<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164045</url>
  </required_header>
  <id_info>
    <org_study_id>206283</org_study_id>
    <secondary_id>AI438-042</secondary_id>
    <nct_id>NCT02164045</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529</brief_title>
  <official_title>Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 From an Extended-Release Formulation of BMS-663068 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current food effect study is being performed to support a Phase 3 study with BMS 663068.
      Results from this study will inform whether patients in the upcoming Phase 3 study can be
      given the flexibility to dose BMS-663068 in the fasted state, if so desired.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose: Other: To assess the effect of food on the steady-state exposure of
      BMS-626529 when administered as BMS 663068 600 mg twice daily (BID) to healthy subjects

      Acquired Immune Deficiency Syndrome (AIDS)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2014</start_date>
  <completion_date type="Actual">July 25, 2014</completion_date>
  <primary_completion_date type="Actual">July 25, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) for BMS-626529 in the presence and absence of food</measure>
    <time_frame>Days 1-4 of Periods 1 and 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) for BMS-626529 in the presence and absence of food</measure>
    <time_frame>Days 1-4 of Periods 1 and 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability endpoints including incidence of Adverse events (AEs), serious AEs, AEs leading to discontinuations, deaths, and the results of vital signs, ECGs, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Approximately up to 41 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-626529</measure>
    <time_frame>Day 4 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration observed at 12 hours postdose (C12) of BMS-626529</measure>
    <time_frame>Day 4 of each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough) of BMS-626529</measure>
    <time_frame>Days 1-4 of each period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Infection, Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>BMS-663068- Fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 tablet twice a day by mouth on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-663068- Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-663068 tablet twice a day by mouth on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-663068</intervention_name>
    <description>BMS-663068</description>
    <arm_group_label>BMS-663068- Fasted</arm_group_label>
    <arm_group_label>BMS-663068- Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical and surgical history, physical examination findings, 12-lead ECG measurements,
             and clinical laboratory test results

          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive

          -  Males and Females, ages 18 to 50 years, inclusive

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin
             (HCG)) within 24 hours prior to the start of study drug

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness as determined by the investigator

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease that could impact upon the absorption of study drug

          -  Any major surgery within 4 weeks of study drug administration

          -  Any gastrointestinal surgery that could impact upon the absorption of study drug

          -  Inability to tolerate oral medication

          -  Recent (within 6 months of study drug administration) history of smoking or current
             smokers

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory
             determinations beyond what is consistent with the target population

          -  Any of the following on 12-lead ECG prior to study drug administration, confirmed by
             repeat:

               -  PR ≥ 210 msec

               -  QRS ≥ 120 msec

               -  QT ≥ 500 msec

               -  QTcF ≥ 450 msec

               -  Positive urine screen for drugs of abuse

          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human
             Immunodeficiency Virus-1 (HIV-1), -2 antibodies, and HIV-1 RNA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

